EANS-Adhoc: SYGNIS Pharma AG / SYGNIS Pharma AG secures further financial resources with shareholder loan

=------------------------------------------------------------------------------- ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. =-------------------------------------------------------------------------------

Capital measures 04.03.2013

Ad hoc-Release according to § 15 WpHG

SYGNIS Pharma AG secures further financial resources with shareholder loan

Heidelberg 4 March 2013 - SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03, Prime Standard) today reports on the granting of a shareholder loan for a total amount of up to EUR 0.7 million by its main shareholders Genetrix Life Sciences, A.B., Uppsala (Sweden) and dievini Hopp BioTech holding GmbH & Co. KG, Walldorf (Germany) with an interest-rate at customary market conditions. As a result this loan, which is payable on demand and subject to a condition precedent, secures the financing of SYGNIS' existing operations, according to the present plans, until mid 2013. The loan is unsecured and is due for repayment not before the end of 2015.

**** end of ad hoc ****

For further information please contact:

SYGNIS Pharma AG Peter Willinger CFO Tel: +49 6221 454 836 Email: willinger@sygnis.de

### Disclaimer This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###

end of announcement euro adhoc =-------------------------------------------------------------------------------

(END) Dow Jones Newswires

   March 04, 2013 04:42 ET (09:42 GMT)- - 04 42 AM EST 03-04-13